Develops and manufactures allergy immunotherapy products. Offers a range of treatment options including injections, sublingual drops, and tablets. Now — the numbers.
This is an established company with proven profits.
Average growth of 13% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $127.2M would still be left in the vault — a solid cushion for hard times.
The market pays 35.3× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 20% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 19% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 13% a year on average.
There is $192.0M in the vault; even if every debt were paid off, $127.2M would remain.
The company’s market value is 35 times its annual profit. Even a small disappointment could hit the price hard.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.